Rao Sudha 4

What Happened
Sudha Rao, Chief Scientific Officer of Kazia Therapeutics (KZIA), was granted 250,000 options over ADSs on June 19, 2026. The options were granted for no consideration (reported as $0 on the Form 4) and carry an exercise price of $18.48 per ADS; they expire on June 19, 2029. This was a compensation award (derivative grant), not a purchase or sale of underlying shares.

Key Details

• Transaction date: June 19, 2026; Form 4 filed June 23, 2026 (filed within the normal two-business-day window).
• Grant: 250,000 options over ADSs; exercise price $18.48 per ADS; options granted for no cash consideration; expiration date June 19, 2029.
• Vesting: One‑third vested on April 13, 2026 (the "Commencement Date"); the remaining two‑thirds vest in equal yearly tranches on each anniversary of that date. Options are forfeited if the reporting person voluntarily departs prior to the first anniversary of the Commencement Date. (See footnote in filing.)
• Shares owned after transaction: not disclosed in the filing.
• Transaction type: Award/Grant (derivative) — code A on Form 4.

Context
This is a standard equity-compensation grant to an executive rather than an open-market purchase or sale. Options give the holder the right to buy ADSs at the stated exercise price ($18.48) through June 19, 2029; they do not represent immediate ownership of shares unless exercised. For retail investors, grants primarily reflect compensation structure and retention incentives rather than a direct signal of insider buying or selling.